MiMedx Group, Inc. (NASDAQ:MDXG) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP increased its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 29.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 221,262 shares of the company's stock after purchasing an additional 50,635 shares during the period. Trexquant Investment LP owned 0.15% of MiMedx Group worth $2,129,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. IMG Wealth Management Inc. acquired a new position in shares of MiMedx Group in the 4th quarter valued at $28,000. Van ECK Associates Corp purchased a new position in shares of MiMedx Group in the 4th quarter valued at about $40,000. Point72 DIFC Ltd lifted its stake in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after purchasing an additional 4,275 shares during the period. Orion Capital Management LLC boosted its holdings in MiMedx Group by 46.3% during the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company's stock worth $69,000 after buying an additional 3,700 shares in the last quarter. Finally, SkyView Investment Advisors LLC increased its holdings in MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock valued at $77,000 after buying an additional 3,000 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDXG has been the subject of several research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com upgraded shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Friday, April 4th.

Remove Ads

MiMedx Group Trading Down 2.0 %

MDXG stock traded down $0.14 during midday trading on Monday, reaching $6.70. 28,594 shares of the company's stock traded hands, compared to its average volume of 694,491. The business has a 50-day moving average price of $7.86 and a two-hundred day moving average price of $8.00. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market capitalization of $987.50 million, a P/E ratio of 12.18 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. Equities research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares of the company's stock, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock valued at $1,130,312 over the last 90 days. 1.30% of the stock is owned by corporate insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.